Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval

GSK wins FDA clearance to expand Arexvy RSV vaccine to at-risk adults ages 18-49 — the broadest age indication in the RSV market. Plus: Novartis claims the only IL-17A approval for pediatric hidradenitis suppurativa, Pfizer shuts down its small biotech R&D support unit, and why manufacturing is the story to watch as the 2026 patent cliff approachesSubstack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #GSK, #Arexvy, #RSVvaccine, #FDA approval, #Novartis, #Cosentyx, #hidradenitis suppurativa, #Pfizer, #Ignite, #Gilead, #lenacapavir, #patent cliff, #Y-mAbs, radiopharmaceutical, #Hyloris, #Unixell, #cell therapy, #manufacturing, #Lilly, #Moderna